NASDAQ: RNA
Atrium Therapeutics Inc Stock Ownership - Who owns Atrium Therapeutics?

Insider buying vs selling

Have Atrium Therapeutics Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when RNA insiders and whales buy or sell their stock.

RNA Shareholders

What type of owners hold Atrium Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Sarah Boyce1.71%265,086$3.48MInsider
W. Michael Flanagan0.35%54,786$719.34kInsider
Steven George Hughes0.28%43,097$565.86kInsider
Kathleen P. Gallagher0.19%28,861$378.94kInsider
Husam Younis0.15%22,657$297.49kInsider
Rocio Martin Hoyos0.11%16,660$218.75kInsider
Brendan R. Winslow0.09%13,601$178.58kInsider
Troy Edward Wilson0.08%11,731$154.03kInsider
Carsten Boess0.07%11,005$144.50kInsider
Simona Skerjanec0.04%5,902$77.49kInsider

1 of 2

RNA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AAPG0.01%10.77%
AARD49.36%46.96%Net Buying
ABUS30.49%69.51%
ABVC3.36%82.65%
ABVX77.17%0.00%

Atrium Therapeutics Stock Ownership FAQ

Who owns Atrium Therapeutics?

Atrium Therapeutics (NASDAQ: RNA) is owned by 0.00% institutional shareholders, 3.09% Atrium Therapeutics insiders, and 96.91% retail investors. Sarah Boyce is the largest individual Atrium Therapeutics shareholder, owning 265,086.00 shares representing 1.71% of the company. Sarah Boyce's Atrium Therapeutics shares are currently valued at $3.50M.

If you're new to stock investing, here's how to buy Atrium Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.